Excedrin Moves to Saatchi

How can you keep pace with an accelerating marketing ecosystem? Join us at Brandweek Sept. 12–16 in Miami alongside leading CMOs, founders and change makers from GatoradeMarriottAlo YogaCampbell'sUncommon James and more. Book now.

NEW YORK Publicis Groupe’s Saatchi & Saatchi has landed Novartis’ Excedrin account without a review, sources said.

The client spent $25 million in measured media on the brand from January through May 2005, per Nielsen Monitor-Plus.

A representative for the New York agency referred calls to client officials, who did immediately respond.

Independent

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in